

## Speakers and Chairs list

In order of speech

- A. D. Ho, University Hospital Heidelberg, Germany  
M. Karck, University Hospital, Heidelberg, Germany  
K. Beyreuther, Network Aging Research Heidelberg, Germany  
E. Wanker, Max-Delbrück Center for Molecular Medicine, Berlin, Germany  
S. Schönland, Amyloidosis Center, University Hospital Heidelberg, Germany  
G. Merlini, Amyloidosis Center, University of Pavia, Italy  
Sir M. Pepys, National Amyloidosis Center, London, Great Britain  
C. M. Dobson, University of Cambridge, Great Britain  
A. Jauch, Institute of Human Genetics, University Heidelberg, Germany  
B. Reif, Technical University München, Germany  
C. Röcken, University Kiel, Germany  
M. Granzow, Institute of Human Genetics, University Heidelberg, Germany  
M. Ramirez-Alvarado, Mayo Clinic, Rochester, USA  
B. Hazenberg, University Medical Center Groningen, The Netherlands  
G. Esposito, Università di Udine, Italy  
V. Bellotti, University College London, Great Britain  
B. Bukau, ZMBH, Heidelberg, Germany  
R. Köhler, Institute of Human Genetics, University Heidelberg, Germany  
M. Fändrich, Ulm University, Germany  
J. Buchner, Technical University München, Germany  
J. Bieschke, Washington University St. Louis, MO, USA  
M. Saraiva, IBMC Molecular Neurobiology, Porto, Portugal  
J. Kelly, The Scripps Research Institute La Jolla, California, USA  
O. Suhr, Umea University, Sweden  
R. L. Comenzo, Tufts University School of Medicine, Boston, USA  
V. Sancharawala, Boston University Amyloidosis Center, USA  
M. Zeier, University Hospital Heidelberg, Germany  
P. Westermark, Uppsala University, Sweden  
G. Westermark, Uppsala University, Sweden  
N. Blank, University Hospital Heidelberg, Germany  
J. Wall, University of Tennessee, Knoxville, USA  
U. Hegenbart, University Hospital Heidelberg, Germany  
A. V. Kristen, University Hospital Heidelberg, Germany  
D. Mereles, University Hospital Heidelberg, Germany  
J. Kollmer, University Hospital Heidelberg, Germany  
K. Lisenko, University Hospital Heidelberg, Germany  
T. Bochtler, University Hospital Heidelberg, Germany  
D. Hose, University Hospital Heidelberg, Germany  
S. Huhn, University Hospital Heidelberg, Germany

## Sponsors



### The Binding Site GmbH

Schwetzingen  
1.000,- Euro



### Celgene GmbH

München  
2.500,- Euro



### Deutsche Gesellschaft für Amyloidoseerkrankungen e.V.

Essen  
1.000,- Euro



### Janssen-Cilag GmbH

Neuss  
2.000,- Euro



### Pfizer

Berlin  
2.000,- Euro



### Sanofi-Aventis Deutschland GmbH

Berlin  
500,- Euro



### Takeda Pharma Vertrieb GmbH & Co. KG

Berlin  
2.000,- Euro



### Prothena

Dublin  
3.000,- Euro

## Access

Heidelberg is about 90 km south of Frankfurt. From Frankfurt International Airport there are several methods of getting to Heidelberg.

For precise information visit the geramy website under „[www.amyloid-geramy.de/the-conference/practical-information](http://www.amyloid-geramy.de/the-conference/practical-information)“



## Contact

Priv.-Doz. Dr. med. Ute Hegenbart  
University Hospital Heidelberg

Phone: +49-6221-56 8001  
Fax: +49-6221-56 4659  
Email: [ute.hegenbart@med.uni-heidelberg.de](mailto:ute.hegenbart@med.uni-heidelberg.de)



Nationales Netzwerk für Amyloidose Erkrankungen



## Conference of the German Network on systemic AL Amyloidosis (GERAMY)

Program

### 20th–21st November 2015

Amyloidosis Center, University Hospital Heidelberg, Germany  
Medizinische Klinik 5, Lecture Hall  
Im Neuenheimer Feld 410, 69120 Heidelberg

 [www.amyloid-geramy.de](http://www.amyloid-geramy.de)

## Welcome Address

Dear colleagues and friends,  
GERAMY, the GERman consortium for systemic light chain (AL) AMYloidosis, was founded in 2012 with funding from the Federal Ministry of Education and Research (BMBF) in the framework of its Rare Disease Initiative. The goal was to establish an interdisciplinary, translational collaboration to increase the knowledge of the pathogenesis of AL amyloidosis and enable new developments to improve diagnosis, therapy and prognosis.

After three years of basic and clinical research by the seven partners, the consortium has now finished its first phase of collaboration. A controlled clinical trial was initiated to test the efficacy and safety of epigallo-catechin-gallate (EGCG) in patients with cardiac AL amyloidosis. In parallel, the molecular basis of the disease has been investigated using genetic, biochemical, cell biological and high-resolution biophysical methods to reveal new molecular targets and to refine diagnosis.

This conference of the GERAMY network aims to:

- Strengthen the connection within the active international amyloidosis research community
- Encourage amyloidosis specialists to share their experience in diagnosis and treatment of several amyloidosis types
- Facilitate exchange between basic researchers, pathologists, geneticists and clinicians to enhance our understanding of the pathogenesis and develop new therapeutic strategies in AL amyloidosis.
- Present and discuss the results of three years of research by the GERAMY collaborators

We are looking forward to meeting YOU in Heidelberg.

*Stefan Schönland, Ute Hegenbart, Marcus Fändrich  
and Erich Wanker*

## Program Friday, 20.11.15

<b>09:00</b>	<b>Registration, welcome reception with coffee</b>
<b>10:00</b>	<b>Opening</b> <i>Prof. A. D. Ho, Prof. M. Karck</i>
<b>10:05</b>	<b>General session</b> Chairs: <i>K. Beyreuther, E. Wanker</i>
10:05	GERAMY, a German interdisciplinary network for AL amyloidosis <i>S. Schönland</i>
10:20	Advances and unmet needs in systemic amyloidosis <i>G. Merlini</i>
10:50	A new approach in systemic amyloidosis: immunotherapeutic removal of amyloid <i>Sir M. Pepys</i>
11:20	Molecular basis of amyloid fibril formation <i>C. Dobson</i>
<b>12:00</b>	<b>Lunch</b>
<b>12:45</b>	<b>Clinical features, genetics and diagnostics in AL amyloidosis</b> Chairs: <i>A. Jauch, B. Reif</i>
12:45	GERAMY SP 3 - Amyloid Registry Kiel – advancing diagnostics of amyloidoses in surgical pathology <i>C. Röcken</i>
13:05	GERAMY SP 2 - Recurrent copy number aberrations in 100 AL amyloidosis patients <i>M. Granzow</i>
13:20	Mechanisms and toxicity of Light chain misfolding and amyloid formation <i>M. Ramirez-Alvarado</i>
<b>14:00</b>	<b>The five best abstracts</b> Chairs: <i>G. Merlini, M. Pepys</i>
<b>15:00</b>	<b>Poster session within Coffee break</b> Chairs: <i>B. Hazenberg, R. Esposito</i>
<b>16:00</b>	<b>Basic science in AL amyloidosis</b> Chairs: <i>V. Belotti, B. Bukau</i>
16:00	GERAMY SP 2 - Amyloid Light Chain Sequence Detection and Evaluation <i>R. Köhler</i>

## Program Friday 20.11.15 and Saturday 21.11.15

### Program Friday, 20.11.15

16:15	GERAMY SP 4 - Analysis of the fibril structure with electron microscopy <i>M. Fändrich</i>
16:35	GERAMY SP 5 - NMR spectroscopic investigations of amyloid aggregates <i>B. Reif</i>
16:55	Not created equal: effect of point mutations on amyloid formation of VL <i>J. Buchner</i>
17:15	GERAMY SP 6 - EGCG modulated aggregation of patient derived light chain amyloid <i>J. Bieschke</i>
17:35	GERAMY SP 7 - Targeting of pathogenic light chain aggregates from patients with small molecules <i>E. Wanker</i>
<b>17:55</b>	<b>End of last session</b>
<b>19:30</b>	<b>Dinner</b> Restaurant at the NH-Hotel Bergheimer Str. 91, 69115 Heidelberg

### Program Saturday, 21.11.15

<b>08:30</b>	<b>Registration</b>
<b>09:00</b>	<b>Therapy in systemic amyloidosis</b> Chairs: <i>M. Saraiva, J. Bieschke</i>
09:00	Mechanisms of TTR amyloidosis misfolding, drug development and treatment <i>J. Kelly</i>
09:30	Results of liver transplantation and current studies on gene therapy in TTR amyloidosis <i>O. Suhr</i>
10:00	Novel Approaches to Patients with AL amyloidosis <i>R. Comenzo</i>
10:30	Current strategies of stem cell transplantation in AL amyloidosis <i>V. Santhorawala</i>
<b>11:00</b>	<b>Coffee</b>

## Saturday 21.11.15

<b>11:30</b>	<b>Biology, clinics and fibril formation in localized and systemic amyloidosis</b> Chairs: <i>M. Zeier, M. Fändrich</i>
11:30	Localized AL amyloidosis <i>P. Westermark</i>
12:00	Imaging in local and systemic amyloidosis <i>B. Hazenberg</i>
12:20	Nanoparticles and Nanobodies: Interaction with Amyloidogenic Proteins <i>G. Esposito</i>
12:40	IAPP in Alzheimers Disease <i>G. Westermark</i>
13:00	Clinical characteristics of AA amyloidosis in Germany <i>N. Blank</i>
<b>13:15</b>	<b>Lunch</b>
<b>14:00</b>	<b>Biology, clinics and prognosis in AL amyloidosis</b> Chairs: <i>J. Wall, C. Röcken</i>
14:00	GERAMY SP 1: EGCG treatment in AL amyloidosis <i>U. Hegenbart</i>
14:15	EGCG treatment in ATTR amyloidosis <i>A. Kristen</i>
14:30	Echocardiography in AL and ATTR amyloidosis <i>D. Mereles</i>
14:45	MRI of peripheral nerves in AL and ATTR amyloidosis <i>J. Kollmer</i>
15:00	Immuno-Phenotype of the plasma cell clone in AL amyloidosis <i>K. Lisenko</i>
15:15	Results of iFISH in AL amyloidosis <i>T. Bochtler</i>
15:30	Plasma cell genetics in multiple myeloma and AL amyloidosis <i>D. Hose</i>
15:45	Results of GWAS in multiple myeloma and AL amyloidosis <i>S. Huhn</i>
<b>16:00</b>	<b>Conclusion End of the Congress / Coffee</b>